<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571801</url>
  </required_header>
  <id_info>
    <org_study_id>DigiSep 01</org_study_id>
    <nct_id>NCT04571801</nct_id>
  </id_info>
  <brief_title>Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics</brief_title>
  <acronym>DigiSep</acronym>
  <official_title>Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Noscendo GmbH, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Economics and Health Care Management, Bielefeld University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Medical Biometry and Informatics, University of Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordination Centre for Clinical Trials (KKS), University of Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Infectious Diseases, University Hospital Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Infectious Diseases and Infection Control, Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Anesthesiology, Heidelberg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AOK Health Insurance, Rheinland, Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barmer Health Insurance, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Techniker Health Insurance, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is triggered by an infection and represents one of the greatest challenges of modern&#xD;
      intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the&#xD;
      earliest possible pathogen detection is of crucial importance. Until now, culture-based&#xD;
      detection methods represent the diagnostic gold standard, although they are characterized by&#xD;
      numerous limitations. Culture-independent molecular diagnostic procedures may represent a&#xD;
      promising alternative. In particular, the concept of plasmatic detection of circulating, free&#xD;
      DNA employing next-generation sequencing (NGS) has shown to be suitable for the detection of&#xD;
      disease-causing pathogens in patients with bloodstream infections.&#xD;
&#xD;
      The DigiSep-Trial is a randomized, controlled, interventional, multicenter trial to&#xD;
      characterize the effect of the combination of NGS-based digital precision diagnostics,&#xD;
      standard-of-care microbiological analyses and optional expert exchanges compared to solely&#xD;
      standard-of-care microbiological analyses in the clinical picture of sepsis / septic shock.&#xD;
      The study examines in 410 patients (n = 205 per arm) with sepsis / septic shock whether the&#xD;
      so-called DOOR-RADAR (Desirability of Outcome Ranking / Response Adjusted for Duration of&#xD;
      Antibiotic Risk) score (representing a combined endpoint including the criteria (1) inpatient&#xD;
      admission time, (2) consumption of antibiotics, (3) mortality and (4) acute renal failure&#xD;
      (ARF)) can be significantly improved, by application of an additional NGS-based diagnostic&#xD;
      concept. We also aim to investigate whether the new diagnostic procedure is cost-effective.&#xD;
      It is postulated that the inpatient admission time, mortality rate, incidence of ARF, the&#xD;
      duration of antimicrobial therapy as well as the costs of complications and outpatient&#xD;
      aftercare can be reduced. Moreover, a significant improvement in the quality of life (QoL) of&#xD;
      the affected patients can be expected.&#xD;
&#xD;
      Extensive preparatory work suggests that NGS-based diagnostics have higher specificity and&#xD;
      sensitivity compared to standard-of-care microbiological analyses for detecting bloodstream&#xD;
      infections. This preliminary work for the DigiSep-Trial with the help of an interventional&#xD;
      study design provides the optimal basis to establish this new concept as part of the national&#xD;
      standard based on the best possible evidence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is a disease which is triggered by an infection and represents one of the greatest&#xD;
      challenges of modern intensive care medicine. With regard to targeted anti-microbial therapy,&#xD;
      the earliest possible pathogen detection is of crucial importance. Until now, culture-based&#xD;
      detection methods represent the gold standard for diagnosis, although numerous limitations&#xD;
      characterize these. In this context, culture-independent molecular biological processes are&#xD;
      an alternative. In particular, the concept of serum detection of circulating, free DNA&#xD;
      employing next-generation sequencing (NGS) seems to represent a promising diagnostic&#xD;
      procedure in patients with bloodstream infections. The applicant's extensive preparatory work&#xD;
      suggests that NGS-based diagnostics using the SIQ score have higher specificity and&#xD;
      sensitivity compared to traditional culture-based methods for detecting bloodstream&#xD;
      infections. This preliminary work for the DigiSep trial with the help of interventional study&#xD;
      design provides the optimal basis to establish this new concept as part of the national&#xD;
      standard based on the best possible evidence. The DigiSep trial is intended to characterize&#xD;
      the effect of the combination of digital precision diagnostics, expert exchange and&#xD;
      culture-based standard diagnostics compared to a purely culture-based conventional diagnosis&#xD;
      in the clinical picture of sepsis / septic shock. The study examines in 410 patients (n = 205&#xD;
      per arm) with sepsis / septic shock whether the so-called DOOR-RADAR score (Desirability of&#xD;
      Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk Score) can be&#xD;
      significantly improved, by application of the NGS. We also aim to also study whether the new&#xD;
      procedure is cost-effective. It is postulated that the inpatient admission time, mortality&#xD;
      rate, incidence of acute renal failure (ARF), the duration of anti-microbial therapy as well&#xD;
      as the costs of complications and outpatient aftercare can be reduced. Also, a significant&#xD;
      improvement in the quality of life of the affected patients can be expected.&#xD;
&#xD;
      As part of the study, the essential data is collected once at the time of sepsis (= onset).&#xD;
      The culture-based diagnostics include the guideline-oriented collection of 2 blood culture&#xD;
      sets (2 x aerobic / 2 x anaerobic) to the onset and three days later. At the same time, serum&#xD;
      samples are obtained for NGS-based pathogen diagnostics. Additional sampling for NGS-based&#xD;
      diagnostics can be made up to day 14 after onset or whenever the attending physician&#xD;
      establishes a clinical indication for the collection of further blood cultures. The&#xD;
      aforementioned cultures vs NGS-based pathogen diagnostics are also accompanied by extended&#xD;
      immunological monitoring from blood plasma samples as well as an NGS-based transcriptome&#xD;
      analysis. The associated sampling takes place at the time of onset, 3, 7 and 14 days after&#xD;
      the beginning of sepsis. Routine microbiological findings from other biological samples (e.g.&#xD;
      surgical swabs, drainage secretions, tracheal secretions, tissue samples) are included in the&#xD;
      evaluation if these were collected three days before or after the extraction of serum samples&#xD;
      for NGS-based diagnostics. The clinical data collection is also carried out at the time of&#xD;
      sepsis (= onset), 3, 7 and 14 days later, analogous to the above-mentioned sample collection.&#xD;
      The final outcome evaluation takes place 28 days (= 28 d) after the onset of sepsis. The&#xD;
      study-related burden on the individual study patient includes a total of 17 ml of whole blood&#xD;
      for NGS-based diagnostics, the four samples of 7.5 ml of whole blood for immunological&#xD;
      monitoring and the four samples of 2.7 ml of whole blood for transcriptome analysis. The&#xD;
      minimum total volume, therefore, amounts to the collection of approximately 75 ml of whole&#xD;
      blood within the first 14 days after the onset of sepsis. The sampling takes place with the&#xD;
      collection of the blood cultures or within the framework of the daily routine blood samples&#xD;
      so that no further venous punctures are required here. Infection parameters such as&#xD;
      procalcitonin (PCT) are carried out within the framework of daily regular blood collection&#xD;
      and therefore, do not require any additional vascular punctures. The same principle applies&#xD;
      to the collection of blood cultures which are routinely obtained as part of standard&#xD;
      diagnostics in patients with suspected or proven sepsis. The required blood samples of two 40&#xD;
      ml of whole blood (each two sets of 2 x aerobic / 2 x anaerobic = 4 x 10 ml = 40 ml)&#xD;
      therefore do not represent any additional burden due to the study. A further additional&#xD;
      burden for the patient concerning invasive procedures or examinations is not expected in the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: Only standard diagnostics (Microbial diagnostics by means of standard culture methods) within the first 72 h after diagnosis&#xD;
Arm 2: Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing) within the first 72 h after diagnosis</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desirability of Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk-Score</measure>
    <time_frame>28 days</time_frame>
    <description>DOOR/RADAR-score [points], (min. 1, max. 5), a lower score indicates a better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease severity</measure>
    <time_frame>at 90 and 180 days</time_frame>
    <description>Long term mortality [%]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease severity</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Hospital length of stay [days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of organ dysfunction/-failure</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Duration of mechanical ventilation [days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of organ dysfunction/-failure</measure>
    <time_frame>during 28 days</time_frame>
    <description>Length of time until shock resolution [hours]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of organ dysfunction/-failure</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Ongoing need for renal replacement therapy [%]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcome</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Cumulative need for anti-infective drugs [days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcome</measure>
    <time_frame>during 28 days</time_frame>
    <description>Beginning of a targeted anti-infective treatment regimen [days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcome</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Utilization of healthcare ressources (outpatient and inpatient) [Euro]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcome</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Policyholder costs (outpatient and inpatient) [Euro]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic outcome</measure>
    <time_frame>at 28, 90, and 180 days</time_frame>
    <description>Disease-related absence from work [days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life (QoL)</measure>
    <time_frame>at 90 and 180 days</time_frame>
    <description>VR-36 questionnaire [points] including 2 summary components, 8 scales, 36 items, a higher score indicates a higher Quality-of-Life (QoL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard diagnostics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard diagnostics + NGS</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard diagnostics</intervention_name>
    <description>Only standard diagnostics (Microbial diagnostics by means of standard culture methods) within the first 72 h after diagnosis of sepsis / septic shock</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Next Generation Sequencing (NGS)</intervention_name>
    <description>Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing) within the first 72 h after diagnosis of sepsis / septic shock</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who develop sepsis or septic shock within &lt; 24 h in accordance with the&#xD;
             new sepsis definition (Sepsis-3) in the above-mentioned participating centers and&#xD;
             consent to participation in the study will be included.&#xD;
&#xD;
        General inclusion criteria:&#xD;
&#xD;
          -  Written consent by the study participant or a legally appointed representative&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Sepsis:&#xD;
&#xD;
          -  Life-threatening organ dysfunction due to a dysregulated immune response on the basis&#xD;
             of a suspected or proven infection&#xD;
&#xD;
          -  Detection of organ dysfunction indicated by SOFA score of ≥ 2 points Alternative:&#xD;
&#xD;
        Change of the quick (q) SOFA score of 2 points as an indication of a sepsis&#xD;
&#xD;
        Or septic shock:&#xD;
&#xD;
          -  Persistent hypotension despite adequate volume substitution, which necessitates the&#xD;
             use of vasopressors, to maintain an arterial medium pressure of &gt; 65 mmHg&#xD;
&#xD;
          -  Serum lactate &gt; 2 mmol/l (18 mg/dl)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Probable discharge of the patient from the intensive care unit within the first 72 h&#xD;
             of initial study inclusion&#xD;
&#xD;
          -  Palliative therapy approach&#xD;
&#xD;
          -  Death of the patient is already foreseeable or inevitable at trial inclusion&#xD;
&#xD;
          -  Patients who have already been included in the study but require re-admission to the&#xD;
             intensive care unit cannot be included a second&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thorsten Brenner, MD</last_name>
    <phone>+49 201 723</phone>
    <phone_ext>1401</phone_ext>
    <email>thorsten.brenner@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc M Berger, MD</last_name>
    <phone>+49 201 723</phone>
    <phone_ext>1401</phone_ext>
    <email>marc.berger@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Markus Weigand, MD</last_name>
      <phone>+49 622156</phone>
      <phone_ext>6110</phone_ext>
      <email>markus.weigand@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heidenheim Hospital</name>
      <address>
        <city>Heidenheim</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Brinkmann, MD</last_name>
      <phone>0049 7321 33</phone>
      <phone_ext>2212</phone_ext>
      <email>alexander.brinkmann@kliniken-heidenheim.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konstanz Hospital</name>
      <address>
        <city>Konstanz</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Wolfgang Krüger, MD</last_name>
      <phone>0049 7531 801</phone>
      <phone_ext>1001</phone_ext>
      <email>anaesthesiologie.kn@glkn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Rosenberger, MD</last_name>
      <phone>0049 7071 29</phone>
      <phone_ext>86622</phone_ext>
      <email>peter.rosenberger@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hendrik Bracht, MD</last_name>
      <phone>0049 731 500</phone>
      <phone_ext>60237</phone_ext>
      <email>Hendrik.Bracht@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital TU München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristina Fuest, MD</last_name>
      <phone>0049 89 4140</phone>
      <phone_ext>8462</phone_ext>
      <email>kristina.fuest@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Diane Bitzinger, MD</last_name>
      <phone>0049 941 944</phone>
      <phone_ext>7801</phone_ext>
      <email>diane.bitzinger@ukr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <phone>+49 931 201</phone>
      <phone_ext>30001</phone_ext>
      <email>meybohm_p@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Evangelisches Krankenhaus Luckau gGmbH</name>
      <address>
        <city>Luckau</city>
        <state>Brandenburg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Simone Lindau</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>5868</phone_ext>
      <email>simone.lindau@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Dr. Horst Schmidt Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Bingold, MD</last_name>
      <phone>0049 611 43</phone>
      <phone_ext>2176</phone_ext>
      <email>tobias.bingold@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Schürholz, MD</last_name>
      <phone>0049 381494</phone>
      <phone_ext>6401</phone_ext>
      <email>anaesthesiologie@med.uni-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Onnen Mörer, MD</last_name>
      <phone>+49 551 396</phone>
      <phone_ext>7744</phone_ext>
      <email>omoerer@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Klaudiusz Suchodolski, MD</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>2489</phone_ext>
      <email>Suchodolski.Klaudiusz@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Lukas Martin, MD</last_name>
      <phone>0049 241 80</phone>
      <phone_ext>80444</phone_ext>
      <email>lmartin@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Evangelisches Krankenhaus Bethel gGmbH Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Friedhelm Bach, MD</last_name>
      <phone>+49 521 772</phone>
      <phone_ext>79102</phone_ext>
      <email>ains@evkb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Putensen, MD</last_name>
      <phone>+49 228 287</phone>
      <phone_ext>14119</phone_ext>
      <email>intensivmedizin@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Timo Brandenburger, MD</last_name>
      <phone>+49 (0)211 81</phone>
      <phone_ext>08900</phone_ext>
      <email>timo.brandenburger@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thorsten Brenner, MD</last_name>
      <phone>0049 201 723</phone>
      <phone_ext>1401</phone_ext>
      <email>thorsten.brenner@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabian Dusse, MD</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>82058</phone_ext>
      <email>fabian.dusse@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sirak Petros, MD</last_name>
      <phone>0341 - 97</phone>
      <phone_ext>127000</phone_ext>
      <email>Sirak.Petros@uniklinik-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Schaller, MD</last_name>
      <phone>0049 30 450</phone>
      <phone_ext>531012</phone_ext>
      <email>stefan.schaller@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Blood culture</keyword>
  <keyword>Next generation sequencing</keyword>
  <keyword>Digital precision diagnostics</keyword>
  <keyword>Desirability of outcome ranking / response adjusted for duration of antibiotic risk (DOOR/RADAR) score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers with access to data are limited to the project partners involved. Researchers will receive pseudonymized data sets for data evaluations. A prerequisite for the transfer of the data to the project partners is the written consent of the patients.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

